GRACE :: Global Resource for Advancing Cancer Education
  • Recent GRACE News & Posts

    • Small Cell Lung Cancer Patients Can Benefit from Immunotherapy [GRACE :: Lung Cancer]
        The current standard of care for SCLC shows limited results with high toxicities. Drs. Soria, Gandhi, and West discuss new ASCO 2015 data that show promise for a subset of patients with PD-L1 expression on Keytruda (pembrolizumab) or Opdivo (nivolumab).
    • Real Hope for Small Cell Lung Cancer Treatments from ASCO 2015 [GRACE :: Lung Cancer]
      Guest post by Dr. Nate Pennell, a board certified medical oncologist at the Taussig Cancer Center at the Cleveland Clinic. He specializes in the treatment of thoracic malignancies with a focus on lung cancer. Dr. Pennell's research interests include clinical trials
    • Immunotherapy Combinations: Best Balance of Activity and Tolerability? [GRACE :: Lung Cancer]
        As more immunotherapeutics become available to treat lung cancer, research must determine how to balance efficacy, toxicities, and cost. That means finding which patients who will benefit from which drugs while maintaining good quality of life. [powerpre
    • Choices Among Immunotherapeutics May Be the Future of Lung Cancer Care [GRACE :: Lung Cancer]
        Novel immunotherapy agent atezolizumab (MPDL3280A) looks superior to Taxotere (docetaxel) in a study, specifically for patients with PD-L1. What are the implications of multiple agents with similar mechanisms of action in the same clinical settings? [pow
    • Immunotherapy for Non-Squamous NSCLC: Should We be Using Biomarker Selection? [GRACE :: Lung Cancer]
        The immune checkpoint inhibitor Opdivo (nivolumab) shows better efficacy than Taxotere (docetaxel) for advanced non-squamous NSCLC, but this was seen only in patients with PD-L1 protein expression on their tumor. Should we be using this as a biomarker? [
    • Dubious ASCO Highlights, BS Endpoints for Ineffective Drugs, and the Credibility Gap [GRACE :: News/Info]
      As many people in our readership know, the ASCO conference is the biggest and most important cancer conference of the year, and there are many competitors for the biggest highlights.  I was therefore annoyed to see that the top-listed highlight in the Medivizor blo
    • Immunotherapy for Squamous Non-Small Cell Lung Cancer [GRACE :: Lung Cancer]
        Research released at the 2015 American Society of Clinical Oncology (ASCO) annual meeting showed great promise for squamous cell lung cancer patients taking the immunotherapy drug Opdivo (nivolumab). But can we predict which patients will do well on it?
    • 5 Common Patient Questions about Molecular Tumor Profiling [GRACE :: Treatments & Symptom Management]
      Guest post by Christine Walko, PharmD, BCOP, FCCPClinical Pharmacogenomic Scientist, DeBartolo Family Personalized Medicine InstituteChair, Clinical Genomic Action CommitteeLee Moffitt Cancer Center, Tampa, FL Back in January, I initially discussed the concept and
    • Serum Testing for Molecular Markers: Circulating Tumor Cells & Circulating Free DNA [GRACE :: Lung Cancer]
        Dr. Jack West reviews new techniques for evaluating mutations from blood, including detection of circulating tumor cells (CTCs) or mutations in circulating free DNA (cfDNA) that can replace at least some tissue biopsies. [powerpress] Download Transcri
    • FAQ: What is Adjuvant Therapy, and How Can It Help Patients with an Early Stage Cancer? [GRACE :: Cancer Basics]
      When patients are found to have a cancer that is at an earlier stage that may be able to be cured with a "local therapy" such as surgery or radiation, we know that these cancers can recur months or years later, .This is presumably because of micrometastatic deposit
    • Myths and Misconceptions About Bronchioloalveolar Carcinoma (BAC) [GRACE :: Lung Cancer]
      Unfortunately, there is as much misinformation as good information about the unusual subtype of lung cancer known as bronchioloalveolar carcinoma (BAC) or adenocarcinoma in situ. Dr. Jack West reviews the top 5 myths. [powerpress] Download PDF Transcript Ple
    • "Exciting Data" Expected for Small Cell Lung Cancer [GRACE :: Lung Cancer]
      Guest post by Dr. Cathy Pietanza, a board-certified medical oncologist at Memorial Sloan Kettering Cancer Center in New York. She specializes in cancers that arise in the lungs and cares for a large number of patients with small cell lung cancer (SCLC).  

Ask Us, Q&A

Immunotherapy Patient Forum 2015 - Register Now


Immunotherapy Patient Forum 2014 Videos

Acquired Resistance Forum Videos


ALK+ Lung Cancer Patient Forum Videos

Join the GRACE Faculty

Lung/Thoracic Cancer Blog
Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog

Subscribe to the GRACEcast Podcast on iTunes

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
   (Free Newsletter)

Recent GRACE Forum Topics

Other Resources

Biomedical Learning Institute